

**I. IN THE CLAIMS:**

This listing of claims below will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-8. (canceled)

9. (currently amended): An isolated monoclonal antibody against a peptide consisting of amino acid residues 375-580 of GPC 3 as set forth in SEQ ID NO: 4, wherein the antibody has a cytotoxic activity in vitro against the cell line [[,]] HepG2 or HuH-7 in the presence of complement or peripheral blood mononuclear cells.

10-22. (Canceled)

23. (previously presented): The antibody claimed in claim 9, wherein the cytotoxic activity is ADCC activity.

24. (previously presented): The antibody claimed in claim 9, wherein the cytotoxic activity is CDC activity.

25. (previously presented): The antibody claimed in claim 9 which is a recombinant antibody.

26. (previously presented): The antibody claimed in claim 25, which is a humanized antibody.

27. (currently amended): The humanized antibody claimed in claim 26, wherein the V region is derived obtained from an antibody of a mammal except human and the C region is derived from a C region of a human antibody.

28. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the H chain is selected from the group consisting of Cy1, Cy2, Cy3 and Cy4.

29. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the L chain is C $\kappa$  or C $\lambda$ .